Yield10 Bioscience, Inc.

Equities

YTEN

US98585K8541

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-15 pm EDT 5-day change 1st Jan Change
2.88 USD -45.25% Intraday chart for Yield10 Bioscience, Inc. -42.40% -49.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000 MT
Top Midday Decliners MT
Yield10 Bioscience to Delist From Nasdaq; Shares Drop MT
Transcript : Yield10 Bioscience, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Yield10 Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Yield10 Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada CI
North American Morning Briefing : Markets Steady -2- DJ
Top Midday Gainers MT
Yield10 Bioscience, Inc. Grants Global License to VISION Bioenergy Oilseeds, LLC for Herbicide Tolerant Camelina Cultivated for Production of Biofuel Feedstock CI
North American Morning Briefing : Stock Futures -2- DJ
Lake Street Downgrades Yield10 Bioscience to Hold From Buy, Cuts Price Target to $0.50 From $3 MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected MT
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data MT
Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program CI
Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil CI
Transcript : Yield10 Bioscience, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Yield10 Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Yield10 Bioscience, Inc. Contemplates Bankruptcy. CI
Yield10 Bioscience, Inc. and Biomar Group Aim to Grow Fish Oil on Land CI
Yield10 Bioscience, Inc. Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Production Technology from Rothamsted Research CI
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care MT
Yield10 Bioscience Acquires License to Commercialize Advanced Omega-3 Technology MT
Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research CI
Chart Yield10 Bioscience, Inc.
More charts
Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
2.88 USD
Average target price
12 USD
Spread / Average Target
+316.67%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW